AIM ImmunoTech CEO and president Thomas K. Equels reports acquisition of common shares worth $3,166.644
AIM•AIM ImmunoTech CEO, president and director Thomas K. Equels purchased 20,299 common shares at $0.156 each, bringing his direct holdings to 210,046 shares.
1. Share purchase
Equels purchased 20,299 shares of AIM ImmunoTech common stock at $0.156 per share. His direct holdings increased to 210,046 shares.
